Advisor Partners LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 6.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,279 shares of the biopharmaceutical company’s stock after purchasing an additional 9,490 shares during the quarter. Pfizer comprises about 0.9% of Advisor Partners LLC’s investment portfolio, making the stock its 19th biggest position. Advisor Partners LLC’s holdings in Pfizer were worth $5,452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently added to or reduced their stakes in PFE. AXA increased its position in shares of Pfizer by 9.2% during the fourth quarter. AXA now owns 5,188,453 shares of the biopharmaceutical company’s stock worth $187,926,000 after acquiring an additional 438,040 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Pfizer by 25.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock worth $10,352,000 after acquiring an additional 57,176 shares during the last quarter. Gagnon Securities LLC increased its position in shares of Pfizer by 61.1% during the first quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,581 shares during the last quarter. Naples Global Advisors LLC increased its position in shares of Pfizer by 5.4% during the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock worth $1,222,000 after acquiring an additional 1,712 shares during the last quarter. Finally, Pennsylvania Trust Co increased its position in shares of Pfizer by 10.9% during the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock worth $28,127,000 after acquiring an additional 67,151 shares during the last quarter. 68.91% of the stock is currently owned by institutional investors.

NYSE:PFE opened at $43.79 on Wednesday. The stock has a market capitalization of $262.28 billion, a P/E ratio of 16.52, a PEG ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a one year low of $33.20 and a one year high of $44.46. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were paid a $0.34 dividend. The ex-dividend date was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a yield of 3.11%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other Pfizer news, VP Loretta V. Cangialosi sold 26,814 shares of Pfizer stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the transaction, the vice president now directly owns 102,360 shares in the company, valued at $4,110,777.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Insiders sold 761,230 shares of company stock valued at $29,054,690 over the last quarter. Insiders own 0.06% of the company’s stock.

A number of analysts have recently issued reports on PFE shares. BMO Capital Markets lifted their target price on Pfizer from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 1st. Morgan Stanley reaffirmed a “buy” rating and set a $43.00 target price on shares of Pfizer in a research report on Monday, June 11th. Jefferies Financial Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $42.00 target price on shares of Pfizer in a research report on Wednesday, July 11th. Finally, Barclays set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 29th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $41.89.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: What are the Benefits of Index Funds?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.